Collegium Pharmaceutical Inc - Pangali Forward P/E COLL

Collegium Pharmaceutical attracts pain therapy experts by providing them with stable career growth. The company's forward P/E on the GURU.Markets terminal linear chart demonstrates market expectations, where 3.50 describes the current status of the metric. Patent protection helps COLL withstand generics, although a narrow specialization in opioids increases legal and regulatory risks in the US.

A forward P/E multiple is used to evaluate the effectiveness of the M&A strategy of Collegium Pharmaceutical (COLL) regarding the acquisition of analgesic brands. This metric is calculated by dividing the current market capitalization by the expected net income for the following year. By analyzing the company's expected P/E ratio, an investor determines the extent of the premium paid for future cash flows. The curve's dynamics reflect market expectations for distribution synergies with clinics. A decrease in this indicator signals that the asset is undervalued relative to its growth potential.